Matthew G. Brown has spent nearly 20 years inside life sciences companies, leading business development, licensing, and corporate development at Becton, Dickinson and Company, Exagen, Monod Bio, and EMD Millipore. He has originated and closed in-licenses, out-licenses, strategic collaborations, OEM supply agreements, and acquisitions.

At Wilson Sonsini, Matthew advises clients on capital formation primarily from Seed through Series B across therapeutics, diagnostics, digital health, medical devices, and research tools. He curates prospective investors for each fundraise campaign, reaching into an established network of hundreds of venture funds, corporate and strategic investors, angel networks, and family offices. Each investor is targeted for thesis fit, risk preference, and alignment with the client's stage of development, capital requirements, and time to the next value inflection event, among other considerations.

Matthew's partnering work runs from partner identification and valuation through deal structure, negotiation, and alliance management. He advises clients on where their assets fit, which counterparties are positioned to act on them, and how to build a partnering strategy that meets a target partner's own innovation mandates.

At Monod Bio, a University of Washington Institute for Protein Design spin-out, Matthew closed the company's first strategic collaboration and renegotiated its exclusive university license, adding six to eight months of capital runway. At Exagen, he expanded a multi-year data-sharing collaboration with GlaxoSmithKline in support of Benlysta.

Within the firm, Matthew leads the Business Advisory Practice's work on applied AI and represents the practice in Wilson Sonsini's firmwide AI initiatives. He also serves on the advisory board of the USC AMI Innovation Fund.